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When performing the GMP process development and
scale up of cellular therapies, a critical review of the
manufacturing process and all the materials and
reagents involved in the production steps is the man-
datory starting point to avoid potential issues related
to the quality and safety of the product. The choice of
the raw materials, plastics and all the additional
equipment that comes into direct contact with the
product must be performed always keeping in mind
that cells, as drug products, cannot be terminally ster-
ilized. The quality of the materials and reagents uti-
lized is therefore directly related to the quality and
degree of purity of the final product. Information
about the available certification must be gathered for
every component and, for critical materials, audits
must be performed to the manufacturing sites to qua-
lify the supplier.
The protocols used for the cell expansion and proces-
sing (if necessary) must be designed trying to reduce at
a minimum the dependence on growth factors and med-
ium supplements. Each additional component that is
added to the culture medium must be justified and its
absence from the final product must be verified with
validated methods. Residues that are not removed dur-
ing the production steps must be accurately measured
and limits must be set after performing a risk evaluation
analysis, to ensure that these process-related impurities
have no adverse effects on the patients.
Supplements such as Fetal Bovine Serum (FBS) are
permitted for the manufacturing of cellular therapies
[1], as long as the serum is sourced from a TSE-free
area. Anyway, the use of a medium containing FBS
should be limited to the cases for which a valid alterna-
tive could not be found. However, continuous research
and development is strongly advised in order to keep up
to date with the latest advances in the field of medium
formulations, in order to be ready to switch to an ani-
mal-free medium as soon as it is feasible. The reduction
of growth factors and supplements is also effective in
controlling the manufacturing costs of a cell therapy
product. An evaluation of the economical aspects and
market sustainability should be performed at an early
stage to increase the chances for an industrial develop-
ment of the cellular product.
The manipulation steps performed during the manu-
facturing stage should be kept to a minimum, in order
to reduce human intervention and decrease the risk of
contamination. Media fill simulations must be per-
formed in purposely stressed conditions to ensure that
the process and the facility are able to support the pro-
duction of a sterile product [2].
When manufacturing patient-specific therapies, exten-
sive efforts should be directed towards the reduction in
the variability of the starting material, that is usually a
tissue sampled from the patient during hospitalization.
Working with well-defined starting material allows for
the set-up of a more robust process with comparable
characteristics between batches dedicated to different
patients. The specifications of the final product for para-
meters such as cell number, purity and potency must be
wide enough to tolerate the normal biological variability
of living organisms, but sufficiently narrowed down to
generate comparable batches of drug. This uniformity is
mandatory for the set up of clinical trials aiming at
gathering a reliable analysis of the safety, tolerability and
efficacy data obtained from treated patients, in order to
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speed up the clinical development of innovative medic-
inal products such as cellular therapies.
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